EYLEA Injection Recommended For Approval Regarding Treatment Of Visual Impairment Due To Diabetic Macular Edema In The European Union
June 27, 2014 at 07:18 AM EDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been recommended for approval by ...